Natera (NASDAQ:NTRA) Releases Earnings Results

Natera (NASDAQ:NTRA - Get Free Report) issued its quarterly earnings results on Tuesday. The medical research company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.31, Briefing.com reports. Natera had a negative return on equity of 26.88% and a negative net margin of 14.01%. The business had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same quarter last year, the company earned ($0.95) earnings per share. The company's quarterly revenue was up 63.9% on a year-over-year basis. Natera updated its FY 2024 guidance to EPS.

Natera Price Performance

NASDAQ:NTRA traded up $25.85 during trading hours on Wednesday, reaching $160.97. 4,523,344 shares of the company were exchanged, compared to its average volume of 1,328,355. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The firm has a market cap of $19.91 billion, a PE ratio of -94.03 and a beta of 1.53. Natera has a twelve month low of $49.97 and a twelve month high of $167.79. The stock's 50-day moving average is $125.09 and its 200-day moving average is $114.52.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on NTRA. BTIG Research boosted their price objective on shares of Natera from $125.00 to $135.00 and gave the company a "buy" rating in a report on Friday, August 9th. The Goldman Sachs Group lifted their target price on Natera from $125.00 to $140.00 and gave the stock a "buy" rating in a report on Wednesday, October 16th. StockNews.com upgraded shares of Natera from a "sell" rating to a "hold" rating in a research note on Wednesday, November 6th. TD Cowen raised their target price on shares of Natera from $155.00 to $175.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Leerink Partners upped their price target on shares of Natera from $140.00 to $150.00 and gave the company an "outperform" rating in a report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $135.06.

Insider Activity

In related news, insider Jonathan Sheena sold 12,000 shares of the company's stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the completion of the transaction, the insider now owns 287,441 shares in the company, valued at $34,783,235.41. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Michael Burkes Brophy sold 608 shares of the business's stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $120.76, for a total transaction of $73,422.08. Following the completion of the sale, the chief financial officer now directly owns 74,014 shares in the company, valued at approximately $8,937,930.64. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Sheena sold 12,000 shares of Natera stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the sale, the insider now directly owns 287,441 shares in the company, valued at approximately $34,783,235.41. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 47,464 shares of company stock worth $5,849,977 over the last 90 days. 7.60% of the stock is currently owned by company insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.